Gujarat Themis Biosyn Shareholders Approve Director Re-appointment and Related Party Transactions via Postal Ballot
Gujarat Themis Biosyn Limited shareholders approved two key resolutions through postal ballot voting concluded on April 20, 2026. The re-appointment of Mrs. Kirandeep Madan as Non-Executive Woman Independent Director received 99.9960% approval, while material related party transactions with Themis Medicare Limited were approved with 52.5598% votes in favor. The e-voting process was conducted from March 19-April 17, 2026, through CDSL's platform with CS Ketan Ravindra Shirwadkar as scrutinizer.

*this image is generated using AI for illustrative purposes only.
Gujarat Themis Biosyn Limited has successfully concluded its postal ballot process, with shareholders approving key corporate governance resolutions through electronic voting. The company announced the voting results on April 20, 2026, following the completion of the e-voting period that ran from March 19 to April 17, 2026.
Director Re-appointment Receives Overwhelming Support
The first resolution concerning the re-appointment of Mrs. Kirandeep Madan (DIN: 00686547) as Non-Executive Woman Independent Director received exceptional shareholder support. This special resolution was passed with an overwhelming majority, demonstrating strong confidence in the proposed appointment.
| Voting Category: | Votes in Favor | Votes Against | Total Votes | Approval Rate |
|---|---|---|---|---|
| Overall Result: | 79330617 | 3204 | 79333821 | 99.9960% |
| Promoter Group: | 76512037 | 0 | 76512037 | 100.0000% |
| Public Institutions: | 1274937 | 0 | 1274937 | 100.0000% |
| Public Non-Institutions: | 1543643 | 3204 | 1546847 | 99.7929% |
Related Party Transaction Approval
The second resolution, an ordinary resolution for approval of material related party transactions with Themis Medicare Limited (TML), also secured shareholder approval, though with a narrower margin. The resolution passed with 52.5598% votes in favor.
| Voting Details: | Votes in Favor | Votes Against | Approval Rate |
|---|---|---|---|
| Total Valid Votes: | 1393892 | 1258122 | 52.5598% |
| Public Institutions: | 19555 | 1255382 | 1.5338% |
| Public Non-Institutions: | 1374337 | 2740 | 99.8010% |
Notably, the promoter and promoter group abstained from voting on this resolution due to their interest in the agenda, with 169770 votes declared invalid from this category.
E-voting Process and Compliance
The postal ballot was conducted in compliance with Section 108 and 110 of the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. CS Ketan Ravindra Shirwadkar of KRS AND CO. served as the scrutinizer for the process.
Key process details include:
- Cut-off Date: Friday, March 13, 2026
- Notice Dispatch: Wednesday, March 18, 2026
- E-voting Period: March 19, 2026 (9:00 AM) to April 17, 2026 (5:00 PM)
- Platform: CDSL's evotingindia.com
- Advertisement: Published in Western Times (English and Gujarati editions) on March 19, 2026
Shareholder Participation
The voting saw significant participation across different shareholder categories. Out of total outstanding shares of 108965265, a total of 79333821 votes were polled for the first resolution, representing 72.8065% of outstanding shares. For the second resolution, 2652014 votes were polled, representing 2.4338% of outstanding shares.
The company has made the voting results and scrutinizer's report available on its website at www.gtbl.in , ensuring transparency and compliance with regulatory requirements. The successful completion of the postal ballot process reinforces the company's commitment to good corporate governance practices.
Historical Stock Returns for Gujarat Themis Biosyn
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.41% | +12.35% | +35.60% | -20.77% | +20.86% | +47.24% |
What strategic initiatives might Mrs. Kirandeep Madan lead as the re-appointed Independent Director to enhance Gujarat Themis Biosyn's corporate governance framework?
How will the approved material related party transactions with Themis Medicare Limited impact Gujarat Themis Biosyn's financial performance and operational synergies in the coming quarters?
What factors contributed to the significant institutional investor opposition (98.5% against) to the related party transaction, and how might this influence future corporate decisions?


































